Unconsciously anti-epidemic has passed 2 years, and many people expect that the battle between humans and the virus, it seems that there is still a long way to go, the recent domestic epidemic has reappeared, and it has not been completely controlled, while the epidemic in Europe and the United States, due to the emergence of the new variant Oficon, has become more severe.
London, England, has declared itself in a "major event state", while the United States has only 20 days after the discovery of the first case of Omikejong infection, the number of Omikeron infections has increased rapidly, and the proportion of infections in some areas has expanded rapidly, and the overall proportion of new cases has reached 72%. As a result, It is very likely that Omikeron will once again replace the Delta strain and become the dominant strain for the sustainable development of the new crown pneumonia epidemic.
Academician Zhong Nanshan also made it clear recently that the development speed of Aomi Kerong is very fast, the infectivity is very strong, and there is a tendency to expand. But how pathogenic and harmful it is is is still being studied.
Whether it is the Olmi kerong or the Delta strain, due to its high degree of contagiousness, the risk of transmission is further increased, controlling the development of the epidemic, responding to the infection of the virus, in addition to effectively maintaining social distancing, protection, and active vaccination (including reinforcing needles), if there is a drug that can effectively respond to the virus infection, it will also be an important weapon for the control of the new crown epidemic.
In fact, since the outbreak of the epidemic, the screening and research of antiviral drugs has been in progress, we hope that some of the original drugs can obtain a certain antiviral effect, but after clinical verification, there is no particularly significant effect of the drug has been screened out, and in the development of new drugs, China and foreign countries, have made some progress, today to share with you some of the recent emergence of some anti-new crown drugs.
The first anti-covid-19 drug in China was approved, maintaining "neutral activity" for Omi kerong
Just in early December, the official website of China's State Food and Drug Administration announced that it had urgently approved antiviral neutralizing antibody combination therapy drugs for the treatment of new coronavirus infections. The drug is a combination of monoclonal antibody drugs that include amphavir maclizumab injection (BRII-196) and romimavir maclumab injection (BRII-198), which are used in combination and can be used by intravenous infusion to test positive for the new crown virus, accompanied by adults at risk of progression to severe illness and children over 12 years of age weighing more than 40 kg.
Professor Zhang Linqi of Tsinghua University, who led the development of this drug, pointed out that the two drugs are a pair of non-competitive new monoclonal neutralizing antibodies obtained from patients recovering from new crown pneumonia, and the application of bioengineering technology reduces the risk of antibody-mediated dependence enhancement, while prolonging the plasma half-life and enabling more durable treatment effects. Clinical trial data showed that both early and late-stage treatment was significantly reduced in both hospitalization and mortality.
It is gratifying that recent studies have found that in vitro neutralization trials, the combination therapy of ampavirusumab/romisvirumab has maintained a good neutralization activity for the Omikejung strain, and for the Delta strain and the Delta+ strain, it also has neutralizing activity. Although the therapeutic effect on the new variant has not yet been clinically verified, in theory, this anti-new crown drug approved by China, administered intravenously, can quickly play a role and seize better treatment opportunities.
The United States urgently approved two new anti-COVID-19 oral drugs from Pfizer and Merck
On December 22, the U.S. Food and Drug Administration (FDA) granted emergency use authorization for new oral antiviral drugs for the treatment of symptomatic COVID-19-infected patients. The drug, developed by Pfizer and called Ritonavir, is available orally for patients over the age of 12 who weigh more than 40 kilograms.
According to relevant information, the indications for this drug are also positive for the new crown virus test result, and patients with a risk of progression to severe disease should be taken as soon as possible after diagnosis or within 5 days after the onset of symptoms. The medication is taken in three tablets twice a day for 5 consecutive days, and possible side effects include hypotastaxia, diarrhea, high blood pressure, and muscle soreness. One study showed that the drug reduced hospitalization and mortality rates for people with mild to moderate COVID-19 infection by 89%.
Just on December 23, the FDA granted an emergency use authorization for another anti-COVID-19 drug for the treatment of adults with mild to moderate COVID-19 infections at risk of serious illness. The drug, developed by Merck under the name molnupiravir, was treated with a 50 percent reduction in hospitalizations according to the results of its Phase III clinical study, which was later shown to have been reduced by 30 percent, and the FDA advisory panel narrowly approved the authorization by a vote of 13 to 11.
The FDA said animal studies have found the drug to have pregnancy injuries and is therefore not recommended for pregnant women. Women who may become pregnant should use reliable methods of contraception if they are treated with monopipvir and within 4 days of the last dose.
Good progress has been made on new antiviral drugs in Israel
On December 22, an Israeli biotechnology company announced that the company's new crown infection treatment drug "Amor-18" had achieved good treatment results in the phase II clinical trial, and 18 moderate to severe COVID-19 patients who received treatment were all recovered and discharged within a few days, including two very serious patients.
This drug is actually not complicated, is a "amorphous calcium carbonate", administered by oral or nebulized inhalation, according to the development company, the drug can regulate the ability of pH changes around each cell, these changes can affect the penetration and replication of coronavirus cells, so the drug has the ability to prevent the spread of the virus in the body, thus playing a role in preventing the deterioration of the disease.
Of course, this drug, due to the small number of experimental cases, whether this drug can really effectively control the new crown infection, but also need further phase III clinical trial results and more clinical trial data to prove that many hospitals in Israel, including 7 hospitals in Brazil, will participate in phase III clinical trials, hoping that in phase III clinical trials, the drug can also channel good treatment effects.